The other side of innovation

Government sponsored comparative effectiveness research is the first step towards allowing Uncle Sam to push a restrictive formulary on more and more Americans – with step one in the process being unfettered (and unregulated) communications efforts. Unless we are aware and vigilant, such cost-think may very well lead to a single-payer system referred to in cost-think as “universal coverage” – but in reality will be nothing short of healthcare rationing. There are many dangerous implications, but the most frightening is the chilling effect so-called comparative effectiveness programs will have on the future of healthcare innovation.

Full details at the Journal of Commercial Biotechnology

Comments are closed.

Do NOT follow this link or you will be banned from the site!